Tissue Heart Valves / Cardiovascular Prosthetic Devices Market Insights, Competitive Landscape and Market Forecast–2026
This report can be delivered to the clients within 7-10 Business Days
TISSUE HEART VALVES MARKET BY PRODUCT TYPE (AORTIC VALVE, MITRAL VALVE, PULMONARY VALVE, AND TRICUSPID VALVE), BY TYPE (STENTED TISSUE HEART VALVES, STENTLESS TISSUE HEART VALVES), BY END USER (HOSPITALS, AMBULATORY SURGICAL CENTERS AND OTHERS), BY GEOGRAPHY IS EXPECTED TO GROW AT A STEADY CAGR FORECAST TILL 2026 OWING TO A RISE IN THE DEMAND OBSERVED FOR MINIMALLY INVASIVE PROCEDURES AND THE RISING PREVALENCE FOR HEART VALVE DISEASES
Global Tissue Heart Valves Market was valued at USD XX million in 2020, growing at a CAGR of XX% during the forecast period from 2021 to 2026. The demand for tissue heart valves is primarily witnessing growth on account of the high prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis, increase in demand for minimally invasive procedures, technological advancements of the tissue heart valves and longer life expectancy of the geriatric population.
TISSUE HEART VALVES MARKET DYNAMICS:
The high prevalence observed in case of heart valve diseases such as the aortic valve degeneration and the aortic stenosis tend to drive the tissue heart valves market. According to a research article by Ancona et al. in the year 2020, “Epidemiology of aortic valve stenosis (AS) and of aortic valve incompetence (AI): is the prevalence of AS/AI similar in different parts of the world?” Aortic stenosis tends to be the second most common valvular disease in United States. The disease is present in about 5% population at the age of 65 years, with an increasing prevalence along with advancing age. A meta-analysis done on predominantly older studies in Europe, the USA and Taiwan resulted a population prevalence of Aortic stenosis of 12.4% and 3.4% suffering from severe aortic stenosis in patients that are 75 years and older.
According to the research article by Wenn et al., in the year 2021, “Aortic Valve Disease”, aortic stenosis is a condition which is more prevalent in the elderly population According to a population-based study, the incidence of aortic stenosis was found to be 0.2% during the fifth decade of life, and reached till 9.8% during the eighth decade of life. Due to the high prevalence observed for heart valve diseases, there will be an increase in the demand for tissue heart valves replacement, thereby driving the market for tissue heart valves.
According to the Center for Disease Control and Prevention, 2019, about 2.5% of the United States population has valvular heart disease, however it is found to be more common in older adults. There are about 25,000 deaths in the U.S. every year due to heart valve disease from other causes than rheumatic disease. The rise in prevalence of heart valve diseases will eventually drive the demand for minimally invasive procedures, in turn driving the demand for tissue heart valves.
However, stringent product approval process, and the high cost associated with minimally invasive procedures are expected to limit the market growth over the forecast period.
TISSUE HEART VALVES MARKET SEGMENT ANALYSIS:
Tissue Heart Valves market by Product Type (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), Tissue Heart Valves market by Type (Stented Tissue Heart Valves, Stentless Tissue Heart Valves), Tissue Heart Valves market by End User (Hospitals, Ambulatory Surgical Centers and Others), and Tissue Heart Valves market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In Tissue heart valves device type segment, the stentless segment is expected to achieve a larger market share during the forecast period. The stentless tissue valves tend to offer advantages over the stented tissue valves such as reduction in rate of thrombosis, more physiological flow pattern and a superior hemodynamics in comparison to the stented valves. The structure offered by the stentless valve prostheses is designed for achieving a more physiological flow pattern when compared with the stented valves. Apart from this in several studies, it has been reported that the stentless valves allow an improved postoperative coronary flow when compared with the stented valves after valve replacement for aortic stenosis. Due to the several advantages that the stentless tissue valves have to offer over the stented tissue valves, their demand will surely experience a surge in the market, thereby leading to an increase in the market of stentless tissue heart valves.
In the research study by Tavakoli et al., in the year 2018, “Biological aortic valve replacement: advantages and optimal indications of stentless compared to stented valve substitutes. A review”, it has been stated that for the stentless aortic root bio-prosthesis, the full root versus sub-coronary implantation offered better early transvalvular gradients, effective orifice area and left ventricular mass regression as well as late freedom from structural valve deterioration in many retrospective studies. Patients suffering from aortic stenosis and other valvular diseases will be more inclined towards the stentless tissue heart valves in contrast to the stented heart tissue valves because of the various benefits offered by them, hence leading to a growth in the demand of stentless tissue heart valves market.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL TISSUE HEART VALVES MARKET:
Among all the regions, North America is expected to account for the largest share in the tissue heart valves market. The increase in the prevalence of valvular heart diseases, favorable reimbursement scenario of tissue heart valves and the rising product approvals for tissue heart valves are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.
According to the Centers for Disease Control and Prevention, 2019, almost 2.5% of the U.S. population has valvular heart disease, but it is more common in older adults. The rheumatic heart disease tends to affect most commonly the mitral valve or the aortic valve, however any valve can be affected and more than one valve can be involved. Approximately 25,000 deaths in the U.S. each year are due to heart valve disease from causes other than rheumatic disease. The bicuspid aortic valve happens in about 1% to 2% of the population and is mostly common amongst men. Due to the rise in the number of patients suffering from valvular diseases, the demand for tissue heart valve replacements will increase, thereby driving the tissue heart valve market.
The rise in product approvals by Food and Drug Administration has also driven the tissue heart valves market in North America. For instance, on May 13, 2021, the FDA approved Edwards Lifesciences LLC Company’s Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System, for use when the mitral valve fails and the patient has a prosthetic ring implanted around the mitral valve in order to help keep the shape.
TISSUE HEART VALVES MARKET KEY PLAYERS:
Some of the key market players operating in the Tissue Heart Valves market includes Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), Braile Biomйdica and Labcor Laboratуrios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, INC., JenaValve Technology Inc., TTK Healthcare Limited, Comed BV, Meril Life Sciences Pvt. Ltd., Beijing Balance Medical Technology Co.,Ltd, Venus Medtech and others.
RECENT DEVELOPMENTAL ACTIVITIES IN TISSUE HEART VALVES MARKET:
? Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the market.
? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
? Key companies dominating the Global Tissue Heart Valves Market.
? Various opportunities available for the other competitor in the Tissue Heart Valves Market space.
? What are the top performing segments in 2020? How these segments will perform in 2026.
? Which is the top-performing regions and countries in the current market scenario?
? Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THE TISSUE HEART VALVES MARKET REPORT STUDY
? Tissue Heart Valves providers
? Research organizations and consulting companies
? Tissue Heart Valves-related organization, association, forum, and other alliances
? Government and corporate offices
? Start-up companies, venture capitalists, and private equity firms
? Distributors and Traders
? Various End-users who want to know more about the Tissue Heart Valves Market and latest technological developments in the Tissue Heart Valves market.
FREQUENTLY ASKED QUESTIONS FOR TISSUE HEART VALVES MARKET:
What is Tissue Heart Valves?
Tissue Heart Valves are also known as the biosynthetic valves, these are harvested from the pig heart valves (porcine) or from the sac surrounding the heart of the cow (bovine). Certain tissue valves are mounted on the frame or stent while others are used directly (stentless).
What is the market for Global Tissue Heart Valves?
Global Tissue Heart Valves Market was valued at USD XX billion in 2020, growing at a CAGR of XX during the forecast period from 2021 to 2026.
What are the drivers for Global Tissue Heart Valves?
The major drivers driving the demand for Tissue Heart Valves are the increasing prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis, the rising demand for minimally invasive procedures, improved technological advancements of the tissue heart valves and longer life expectancy of the geriatric population.
What are the key players operating in Global Tissue Heart Valves?
Some of the key market players operating in the Tissue Heart Valves market includes Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), and others.
What regions has the highest share in Tissue Heart Valves market?
North America is expected to dominate the overall Tissue Heart Valves market during the forecast period, 2021 to 2026. This domination is due to the rising prevalence of heart valvular diseases, rising product approvals in the North American region and increasing reimbursement policies pertaining to the tissue heart valves.
TISSUE HEART VALVES MARKET BY PRODUCT TYPE (AORTIC VALVE, MITRAL VALVE, PULMONARY VALVE, AND TRICUSPID VALVE), BY TYPE (STENTED TISSUE HEART VALVES, STENTLESS TISSUE HEART VALVES), BY END USER (HOSPITALS, AMBULATORY SURGICAL CENTERS AND OTHERS), BY GEOGRAPHY IS EXPECTED TO GROW AT A STEADY CAGR FORECAST TILL 2026 OWING TO A RISE IN THE DEMAND OBSERVED FOR MINIMALLY INVASIVE PROCEDURES AND THE RISING PREVALENCE FOR HEART VALVE DISEASES
Global Tissue Heart Valves Market was valued at USD XX million in 2020, growing at a CAGR of XX% during the forecast period from 2021 to 2026. The demand for tissue heart valves is primarily witnessing growth on account of the high prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis, increase in demand for minimally invasive procedures, technological advancements of the tissue heart valves and longer life expectancy of the geriatric population.
TISSUE HEART VALVES MARKET DYNAMICS:
The high prevalence observed in case of heart valve diseases such as the aortic valve degeneration and the aortic stenosis tend to drive the tissue heart valves market. According to a research article by Ancona et al. in the year 2020, “Epidemiology of aortic valve stenosis (AS) and of aortic valve incompetence (AI): is the prevalence of AS/AI similar in different parts of the world?” Aortic stenosis tends to be the second most common valvular disease in United States. The disease is present in about 5% population at the age of 65 years, with an increasing prevalence along with advancing age. A meta-analysis done on predominantly older studies in Europe, the USA and Taiwan resulted a population prevalence of Aortic stenosis of 12.4% and 3.4% suffering from severe aortic stenosis in patients that are 75 years and older.
According to the research article by Wenn et al., in the year 2021, “Aortic Valve Disease”, aortic stenosis is a condition which is more prevalent in the elderly population According to a population-based study, the incidence of aortic stenosis was found to be 0.2% during the fifth decade of life, and reached till 9.8% during the eighth decade of life. Due to the high prevalence observed for heart valve diseases, there will be an increase in the demand for tissue heart valves replacement, thereby driving the market for tissue heart valves.
According to the Center for Disease Control and Prevention, 2019, about 2.5% of the United States population has valvular heart disease, however it is found to be more common in older adults. There are about 25,000 deaths in the U.S. every year due to heart valve disease from other causes than rheumatic disease. The rise in prevalence of heart valve diseases will eventually drive the demand for minimally invasive procedures, in turn driving the demand for tissue heart valves.
However, stringent product approval process, and the high cost associated with minimally invasive procedures are expected to limit the market growth over the forecast period.
TISSUE HEART VALVES MARKET SEGMENT ANALYSIS:
Tissue Heart Valves market by Product Type (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), Tissue Heart Valves market by Type (Stented Tissue Heart Valves, Stentless Tissue Heart Valves), Tissue Heart Valves market by End User (Hospitals, Ambulatory Surgical Centers and Others), and Tissue Heart Valves market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In Tissue heart valves device type segment, the stentless segment is expected to achieve a larger market share during the forecast period. The stentless tissue valves tend to offer advantages over the stented tissue valves such as reduction in rate of thrombosis, more physiological flow pattern and a superior hemodynamics in comparison to the stented valves. The structure offered by the stentless valve prostheses is designed for achieving a more physiological flow pattern when compared with the stented valves. Apart from this in several studies, it has been reported that the stentless valves allow an improved postoperative coronary flow when compared with the stented valves after valve replacement for aortic stenosis. Due to the several advantages that the stentless tissue valves have to offer over the stented tissue valves, their demand will surely experience a surge in the market, thereby leading to an increase in the market of stentless tissue heart valves.
In the research study by Tavakoli et al., in the year 2018, “Biological aortic valve replacement: advantages and optimal indications of stentless compared to stented valve substitutes. A review”, it has been stated that for the stentless aortic root bio-prosthesis, the full root versus sub-coronary implantation offered better early transvalvular gradients, effective orifice area and left ventricular mass regression as well as late freedom from structural valve deterioration in many retrospective studies. Patients suffering from aortic stenosis and other valvular diseases will be more inclined towards the stentless tissue heart valves in contrast to the stented heart tissue valves because of the various benefits offered by them, hence leading to a growth in the demand of stentless tissue heart valves market.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL TISSUE HEART VALVES MARKET:
Among all the regions, North America is expected to account for the largest share in the tissue heart valves market. The increase in the prevalence of valvular heart diseases, favorable reimbursement scenario of tissue heart valves and the rising product approvals for tissue heart valves are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.
According to the Centers for Disease Control and Prevention, 2019, almost 2.5% of the U.S. population has valvular heart disease, but it is more common in older adults. The rheumatic heart disease tends to affect most commonly the mitral valve or the aortic valve, however any valve can be affected and more than one valve can be involved. Approximately 25,000 deaths in the U.S. each year are due to heart valve disease from causes other than rheumatic disease. The bicuspid aortic valve happens in about 1% to 2% of the population and is mostly common amongst men. Due to the rise in the number of patients suffering from valvular diseases, the demand for tissue heart valve replacements will increase, thereby driving the tissue heart valve market.
The rise in product approvals by Food and Drug Administration has also driven the tissue heart valves market in North America. For instance, on May 13, 2021, the FDA approved Edwards Lifesciences LLC Company’s Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System, for use when the mitral valve fails and the patient has a prosthetic ring implanted around the mitral valve in order to help keep the shape.
TISSUE HEART VALVES MARKET KEY PLAYERS:
Some of the key market players operating in the Tissue Heart Valves market includes Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), Braile Biomйdica and Labcor Laboratуrios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, INC., JenaValve Technology Inc., TTK Healthcare Limited, Comed BV, Meril Life Sciences Pvt. Ltd., Beijing Balance Medical Technology Co.,Ltd, Venus Medtech and others.
RECENT DEVELOPMENTAL ACTIVITIES IN TISSUE HEART VALVES MARKET:
- On May 13, 2021, FDA had approved the Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve (THV) System to replace a diseased heart valve without open-heart surgery.
- On December 14, 2020, Foldax®, Inc. had announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to initiate a U.S. clinical study of its Tria™ biopolymer mitral surgical heart valve.
- On September 10, 2020, the leading transcatheter heart valve medical device player in China had announced their joint venture with Jilin Changchun Haoyue Halal Meat Co., Ltd ('Haoyue Group'). The Venus Medtech and Venus Haoyue Medtech are aiming to provide total treatment solutions for heart valve diseases from the source of biomaterials.
? Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the market.
? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
? Key companies dominating the Global Tissue Heart Valves Market.
? Various opportunities available for the other competitor in the Tissue Heart Valves Market space.
? What are the top performing segments in 2020? How these segments will perform in 2026.
? Which is the top-performing regions and countries in the current market scenario?
? Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THE TISSUE HEART VALVES MARKET REPORT STUDY
? Tissue Heart Valves providers
? Research organizations and consulting companies
? Tissue Heart Valves-related organization, association, forum, and other alliances
? Government and corporate offices
? Start-up companies, venture capitalists, and private equity firms
? Distributors and Traders
? Various End-users who want to know more about the Tissue Heart Valves Market and latest technological developments in the Tissue Heart Valves market.
FREQUENTLY ASKED QUESTIONS FOR TISSUE HEART VALVES MARKET:
What is Tissue Heart Valves?
Tissue Heart Valves are also known as the biosynthetic valves, these are harvested from the pig heart valves (porcine) or from the sac surrounding the heart of the cow (bovine). Certain tissue valves are mounted on the frame or stent while others are used directly (stentless).
What is the market for Global Tissue Heart Valves?
Global Tissue Heart Valves Market was valued at USD XX billion in 2020, growing at a CAGR of XX during the forecast period from 2021 to 2026.
What are the drivers for Global Tissue Heart Valves?
The major drivers driving the demand for Tissue Heart Valves are the increasing prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis, the rising demand for minimally invasive procedures, improved technological advancements of the tissue heart valves and longer life expectancy of the geriatric population.
What are the key players operating in Global Tissue Heart Valves?
Some of the key market players operating in the Tissue Heart Valves market includes Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), and others.
What regions has the highest share in Tissue Heart Valves market?
North America is expected to dominate the overall Tissue Heart Valves market during the forecast period, 2021 to 2026. This domination is due to the rising prevalence of heart valvular diseases, rising product approvals in the North American region and increasing reimbursement policies pertaining to the tissue heart valves.
1. TISSUE HEART VALVES REPORT INTRODUCTION
2. TISSUE HEART VALVES EXECUTIVE SUMMARY
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 U.K.
3.3 Japan
4 TISSUE HEART VALVES KEY FACTORS ANALYSIS
4.1 Tissue Heart Valves Market Drivers
4.1.1 High prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis
4.1.2 Increase in demand for minimally invasive procedures
4.1.3 Technological advancements of the tissue heart valves
4.1.4 Longer life expectancy of the geriatric population
4.2 Tissue Heart Valves Market Restraints and Challenges
4.2.1 Stringent product approval process
4.2.2 High cost associated with minimally invasive procedures
4.3 Tissue Heart Valves Market Opportunities
4.3.1 Advanced treatment options for valvular diseases
5 TISSUE HEART VALVES PORTER’S FIVE FORCES ANALYSIS
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6 COVID-19 IMPACT ANALYSIS ON TISSUE HEART VALVES MARKET
7. TISSUE HEART VALVES MARKET LAYOUT
7.1 By Type
7.1.1 Stented Tissue Heart Valves
7.1.2 Stentless Tissue Heart Valves
7.2 By Product Type
7.2.1 Mitral Valve
7.2.2 Aortic Valve
7.2.3 Pulmonary Valve
7.2.4 Tricuspid Valve
7.3 By End User
7.3.1 Hospitals
7.3.2 Ambulatory Surgical Centers
7.3.3 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 North America Tissue Heart Valves Market, by Type
7.5.1.2 North America Tissue Heart Valves Market, by End User
7.5.1.3 North America Tissue Heart Valves Market, by Product Type
7.5.1.4 North America Tissue Heart Valves Market, by Country
7.5.1.4.1 United States
7.5.1.4.2 Canada
7.5.1.4.3 Mexico
7.5.2 Europe
7.5.2.1 Europe Tissue Heart Valves Market, by Type
7.5.2.2 Europe Tissue Heart Valves Market, by End User
7.5.2.3 Europe Tissue Heart Valves Market, by Product Type
7.5.2.4 Europe Tissue Heart Valves Market, by Country
7.5.2.4.1 France
7.5.2.4.2 Germany
7.5.2.4.3 United Kingdom
7.5.2.4.4 Italy
7.5.2.4.5 Spain
7.5.2.4.6 Russia
7.5.2.4.7 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 Asia-Pacific Tissue Heart Valves Market, by Type
7.5.3.2 Asia-Pacific Tissue Heart Valves Market, by End User
7.5.3.3 Asia-Pacific Tissue Heart Valves Market, by Product Type
7.5.3.4 Asia-Pacific Tissue Heart Valves Market, by Country
7.5.3.4.1 China
7.5.3.4.2 Japan
7.5.3.4.3 India
7.5.3.4.4 Australia
7.5.3.4.5 South Korea
7.5.3.4.6 Rest of Asia Pacific
7.5.4 Rest of the World (RoW)
7.5.4.1 RoW Tissue Heart Valves Market, by Type
7.5.4.2 RoW Tissue Heart Valves Market, by End User
7.5.4.3 RoW Tissue Heart Valves Market, by Product Type
7.5.4.4 RoW Tissue Heart Valves Market, by Region
7.5.4.4.1 Middle East
7.5.4.4.2 Africa
7.5.4.4.3 South America
8. TISSUE HEART VALVES GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. TISSUE HEART VALVES COMPANY AND PRODUCT PROFILES
9.1 Abbott
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 Boston Scientific Corporation
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 Edward Lifesciences Corporation
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 Medtronic
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 Sorin Group (LivaNova PLC)
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 Braile Biomйdica
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 Labcor Laboratуrios
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 Colibri Heart Valve
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 ON-X LIFE TECHNOLOGIES, INC.
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 JenaValve Technology Inc.,
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 TTK Healthcare Limited
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Comed BV
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 Meril Life Sciences Pvt. Ltd.,
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 Beijing Balance Medical Technology Co.,Ltd
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
9.15 Venus Medtech
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4 Product Listing
9.15.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
2. TISSUE HEART VALVES EXECUTIVE SUMMARY
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 U.K.
3.3 Japan
4 TISSUE HEART VALVES KEY FACTORS ANALYSIS
4.1 Tissue Heart Valves Market Drivers
4.1.1 High prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis
4.1.2 Increase in demand for minimally invasive procedures
4.1.3 Technological advancements of the tissue heart valves
4.1.4 Longer life expectancy of the geriatric population
4.2 Tissue Heart Valves Market Restraints and Challenges
4.2.1 Stringent product approval process
4.2.2 High cost associated with minimally invasive procedures
4.3 Tissue Heart Valves Market Opportunities
4.3.1 Advanced treatment options for valvular diseases
5 TISSUE HEART VALVES PORTER’S FIVE FORCES ANALYSIS
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6 COVID-19 IMPACT ANALYSIS ON TISSUE HEART VALVES MARKET
7. TISSUE HEART VALVES MARKET LAYOUT
7.1 By Type
7.1.1 Stented Tissue Heart Valves
7.1.2 Stentless Tissue Heart Valves
7.2 By Product Type
7.2.1 Mitral Valve
7.2.2 Aortic Valve
7.2.3 Pulmonary Valve
7.2.4 Tricuspid Valve
7.3 By End User
7.3.1 Hospitals
7.3.2 Ambulatory Surgical Centers
7.3.3 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 North America Tissue Heart Valves Market, by Type
7.5.1.2 North America Tissue Heart Valves Market, by End User
7.5.1.3 North America Tissue Heart Valves Market, by Product Type
7.5.1.4 North America Tissue Heart Valves Market, by Country
7.5.1.4.1 United States
7.5.1.4.2 Canada
7.5.1.4.3 Mexico
7.5.2 Europe
7.5.2.1 Europe Tissue Heart Valves Market, by Type
7.5.2.2 Europe Tissue Heart Valves Market, by End User
7.5.2.3 Europe Tissue Heart Valves Market, by Product Type
7.5.2.4 Europe Tissue Heart Valves Market, by Country
7.5.2.4.1 France
7.5.2.4.2 Germany
7.5.2.4.3 United Kingdom
7.5.2.4.4 Italy
7.5.2.4.5 Spain
7.5.2.4.6 Russia
7.5.2.4.7 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 Asia-Pacific Tissue Heart Valves Market, by Type
7.5.3.2 Asia-Pacific Tissue Heart Valves Market, by End User
7.5.3.3 Asia-Pacific Tissue Heart Valves Market, by Product Type
7.5.3.4 Asia-Pacific Tissue Heart Valves Market, by Country
7.5.3.4.1 China
7.5.3.4.2 Japan
7.5.3.4.3 India
7.5.3.4.4 Australia
7.5.3.4.5 South Korea
7.5.3.4.6 Rest of Asia Pacific
7.5.4 Rest of the World (RoW)
7.5.4.1 RoW Tissue Heart Valves Market, by Type
7.5.4.2 RoW Tissue Heart Valves Market, by End User
7.5.4.3 RoW Tissue Heart Valves Market, by Product Type
7.5.4.4 RoW Tissue Heart Valves Market, by Region
7.5.4.4.1 Middle East
7.5.4.4.2 Africa
7.5.4.4.3 South America
8. TISSUE HEART VALVES GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. TISSUE HEART VALVES COMPANY AND PRODUCT PROFILES
9.1 Abbott
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 Boston Scientific Corporation
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 Edward Lifesciences Corporation
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 Medtronic
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 Sorin Group (LivaNova PLC)
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 Braile Biomйdica
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 Labcor Laboratуrios
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 Colibri Heart Valve
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 ON-X LIFE TECHNOLOGIES, INC.
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 JenaValve Technology Inc.,
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 TTK Healthcare Limited
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Comed BV
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 Meril Life Sciences Pvt. Ltd.,
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 Beijing Balance Medical Technology Co.,Ltd
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
9.15 Venus Medtech
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4 Product Listing
9.15.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
